Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 2,783 shares of the stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $5.59, for a total transaction of $15,556.97. Following the completion of the transaction, the chief financial officer now directly owns 63,608 shares of the company’s stock, valued at $355,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Kevin Dennis Green also recently made the following trade(s):
- On Monday, December 10th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The stock was sold at an average price of $5.35, for a total transaction of $14,889.05.
- On Monday, November 12th, Kevin Dennis Green sold 2,783 shares of Cerus stock. The stock was sold at an average price of $5.56, for a total transaction of $15,473.48.
Shares of CERS opened at $5.61 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.48 and a quick ratio of 3.17. Cerus Co. has a 1-year low of $3.77 and a 1-year high of $8.05. The company has a market cap of $774.78 million, a PE ratio of -10.02 and a beta of 1.33.
Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11). Cerus had a negative net margin of 74.95% and a negative return on equity of 68.90%. The business had revenue of $15.40 million during the quarter, compared to analysts’ expectations of $15.40 million. During the same period last year, the company posted ($0.12) EPS. The company’s revenue was up 42.6% on a year-over-year basis. As a group, sell-side analysts expect that Cerus Co. will post -0.43 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in CERS. BlackRock Inc. boosted its position in Cerus by 9.6% during the second quarter. BlackRock Inc. now owns 10,405,997 shares of the biotechnology company’s stock worth $69,408,000 after acquiring an additional 909,836 shares during the last quarter. ARK Investment Management LLC raised its stake in shares of Cerus by 14.1% in the 3rd quarter. ARK Investment Management LLC now owns 6,499,032 shares of the biotechnology company’s stock valued at $46,858,000 after acquiring an additional 803,661 shares during the period. PNC Financial Services Group Inc. purchased a new position in shares of Cerus in the 3rd quarter valued at $4,815,000. Man Group plc raised its stake in shares of Cerus by 116.2% in the 3rd quarter. Man Group plc now owns 1,043,123 shares of the biotechnology company’s stock valued at $7,521,000 after acquiring an additional 560,723 shares during the period. Finally, Fosun International Ltd purchased a new position in shares of Cerus in the 3rd quarter valued at $3,275,000. Hedge funds and other institutional investors own 60.58% of the company’s stock.
A number of research analysts have recently weighed in on CERS shares. BidaskClub cut shares of Cerus from a “sell” rating to a “strong sell” rating in a research note on Wednesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 price objective on shares of Cerus in a research note on Tuesday, December 18th. Zacks Investment Research cut shares of Cerus from a “hold” rating to a “sell” rating in a research note on Monday, January 7th. Finally, ValuEngine cut shares of Cerus from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $9.00.
TRADEMARK VIOLATION NOTICE: “Kevin Dennis Green Sells 2,783 Shares of Cerus Co. (CERS) Stock” was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.thestockobserver.com/2019/01/14/kevin-dennis-green-sells-2783-shares-of-cerus-co-cers-stock.html.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
Featured Article: Stock Selection – What is cash flow?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.